Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 aggregate principal amount of its 6.47% Senior Notes due September 30, 2030 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 53,500,000 aggregate principal amount of its 6.477.25% Senior Notes due September December 30, 2030 2029 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue issuance and sale of $110,000,000 144,812,500 aggregate principal amount of its 6.475.22% Senior Secured Notes due September March 30, 2030 2025 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section Article 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 U.S.$200,000,000 aggregate principal amount of its 6.474.53% Senior Notes due September July 30, 2030 2025 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13)14. The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 25,000,000 aggregate principal amount of its 6.478.5% Senior Notes due September December 30, 2030 2020 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company Issuer will authorize the issue and sale of $110,000,000 113,000,000 aggregate principal amount of its 6.474.34% Senior Notes due September 30December 14, 2030 2008 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 1315). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company Issuer will authorize the issue and sale of $110,000,000 150,000,000 aggregate principal amount of its 6.474.19% Senior Notes due September 30June 15, 2030 2023 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 25,000,000 aggregate principal amount of its 6.473.86% Senior Notes due September 30December 22, 2030 2021 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 aggregate 25,000,000 principal amount of its 6.475.29% Senior Notes due September 30March 2, 2030 2020 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 350,000,000 aggregate principal amount of its 6.473.44% Senior Notes due September 30December 29, 2030 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 150,000,000 aggregate principal amount of its 6.475.71% Senior Notes due September 30December 18, 2030 2012 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 150,000,000 aggregate principal amount of its 6.474.53% Senior Notes due September 30April 19, 2030 2032 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1Schedule 1.1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 11,000,000 aggregate principal amount of its 6.478.01% Senior Notes due September 30August 11, 2030 2015 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 25,000,000 aggregate principal amount of its 6.473.31% Senior Notes due September 30December 15, 2030 2022 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 145,000,000 aggregate principal amount of its 6.477.06% Senior Notes due September 30December 18, 2030 2008 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13"1998 NOTES"). The Notes terms "NOTE" and "NOTES" as used herein shall include each 1998 Note delivered pursuant to any provision of this Agreement and each Note delivered in substitution or exchange for any such Note pursuant to any such provision. The form of each Note shall be substantially in the form set out in of Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement1 hereto.

Authorization of Notes. The Company will authorize the issue and sale of (i) $110,000,000 140,000,000 aggregate principal amount of its 6.476.63% Senior Notes due September 30May 13, 2030 2019 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue issuance and sale of $110,000,000 50,000,000 aggregate principal amount of its 6.474.24% Senior Notes due September 30December 15, 2030 2044 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out forth in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 175,000,000 aggregate principal amount of its 6.475.52% Series A Senior Notes due September 30October 22, 2030 2029 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 30,000,000 aggregate principal amount of its 6.474.74% Senior Notes due September 30February 26, 2030 2020 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 250,000,000 aggregate principal amount of its 6.474.12% Senior Notes Notes, Series E, due September 30March 5, 2030 2022 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 100,000,000 aggregate principal amount of its 6.475.38% Senior Notes due September 30May 17, 2030 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 75,000,000 aggregate principal amount of its 6.474.00% Senior Notes due September 30August 8, 2030 2026 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 125,000,000 aggregate principal amount of its 6.473.25% Senior Notes due September 30February 25, 2030 2028 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 75,000,000 aggregate principal amount of its 6.476.89% Senior Guaranteed Notes due September 30May 25, 2030 2014 (the “"Notes”, ," such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 350,000,000 aggregate principal amount of its 6.474.27% Senior Notes due September 30January 31, 2030 2031 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Schedule 1‑A. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 70,000,000 aggregate principal amount of its 6.47% Senior Unsecured Notes due September July 30, 2030 2026 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 225,000,000 aggregate principal amount of its 6.47% Senior Notes due September 30May 19, 2030 2025 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 40,000,000 aggregate principal amount of its 6.475.59% Senior Notes due September 3011, 2030 2018 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 125,000,000 aggregate principal amount of its 6.474.50% Senior Unsecured Notes due September 30February 11, 2030 2026 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale delivery of $110,000,000 250,000,000 aggregate principal amount of its 6.477% Convertible Senior Notes due September 30, 2030 2018 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 139.2(b) or Section 12). The Notes shall be substantially in the form set out in Exhibit 1, subject to the changes contemplated thereunder for Exchange Notes. Certain capitalized and other terms used in this Note Purchase Agreement (this “Agreement”) are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.B.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 £57,000,000 aggregate principal amount of its 6.477.78% Series I Senior Guaranteed Notes due September 30July 31, 2030 2018 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1314). The Notes issued on Closing shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 400,000,000 aggregate principal amount of its 6.475.60% Senior Unsecured Notes due September 30November 29, 2030 2016 (the “"Notes”", such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out forth in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references B. References to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 50,000,000 aggregate principal amount of its 6.472.94% Senior Notes due September 30November 15, 2030 2029 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 200,000,000 aggregate principal amount of its 6.47% Senior Notes due September 3015, 2030 2029 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 28,000,000 aggregate principal amount of its 6.474.38% Senior Notes due September 30April 1, 2030 2042 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 175,000,000 aggregate principal amount of its 6.475.20% Senior Notes Notes, due September 30June 15, 2030 2018 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 450,000,000 aggregate principal amount of its 6.473.43% Senior Notes due September 30August 31, 2030 2050 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (a) $110,000,000 40,000,000 aggregate principal amount of its 6.473.76% Senior Notes Notes, due September 30January 15, 2030 2052 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 aggregate 10,000,000 principal amount of its 6.477.15% Senior Notes due September 30December 15, 2030 2018 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 11 with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company Companies will authorize the issue and sale of $110,000,000 20,000,000 aggregate principal amount of its 6.47their 7.43% Senior Secured Notes due September 30December 31, 2030 2014 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 30,000,000 aggregate principal amount of its 6.476.00% Senior Notes due September 30August 7, 2030 2023 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 800,000,000 aggregate principal amount of its 6.475.00% Senior Secured Notes due September 3015, 2030 2037 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1the Indenture. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 15.4 shall govern.

Authorization of Notes. The Company will authorize has authorized the issue issuance and sale of $110,000,000 50,000,000 aggregate principal amount of its 6.474.76% Senior Notes due September 30November 1, 2030 2019 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out forth in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 35,000,000 aggregate principal amount of its 6.473.53% Senior Notes due September 3025, 2030 2037 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 150,000,000 aggregate principal amount of its 6.474.84% Senior Notes due September 30April 27, 2030 2020 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale of $110,000,000 40,000,000 aggregate principal amount of its 6.474.53% Senior Notes Notes, Series 2012F, due September 301, 2030 2032, (the “Notes.”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 115,000,000 aggregate principal amount of its 6.473.82% Senior Notes Notes, Series A, due September 30February 19, 2030 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 11.1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 €175,000,000 aggregate principal amount of its 6.474.50% Senior Notes due September 30March 9, 2030 2014 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 80,000,0000 aggregate principal amount of its 6.474.29% Senior Notes Notes, Series M, due September 30, 2030 2049 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 50,000,000 aggregate principal amount of its 6.474.33% Senior Notes due September 30May 15, 2030 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 30,000,000 aggregate principal amount of its 6.473.24% Senior Notes due September 30, 2030 2050 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 75,000,000 aggregate principal amount of its 6.476.89% Senior Guaranteed Notes due September 30May 25, 2030 2014 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 200,000,000 aggregate principal amount of its 6.474.87% Senior Secured Notes due September 30February 8, 2030 2021 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 11.1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 100,000,000 aggregate principal amount of its 6.475.28% Senior Notes due September 30October 15, 2030 2029 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 12,000,000 aggregate principal amount of its 6.476.79% Senior Notes due September 30December15, 2030 2007 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13Section13 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1Exhibit1, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule BScheduleB; and references to a “Schedule” Schedule or an “Exhibit” Exhibit are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 100,000,000 aggregate principal amount of its 6.47% Senior Unsecured Notes due September 30, 2030 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 50,000,000 aggregate principal amount of its 6.476.12% Senior Notes due September 30April 28, 2030 2016 (the “"Notes”", such term to include any such notes issued in substitution therefor pursuant to Section SECTION 13). The Notes shall be substantially in the form set out in Exhibit EXHIBIT 1. Certain capitalized and other terms used in this Agreement are defined in Schedule SCHEDULE B; and references to a “Schedule” "SCHEDULE" or an “Exhibit” "EXHIBIT" are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 67,000,000 aggregate principal amount of its 6.479.78% Series G Senior Notes due September 30December 1, 2030 2018 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 100,000,000 aggregate principal amount of its 6.475.12% Senior Notes due September 30December 16, 2030 2041 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 aggregate principal amount of its 6.47500,000,000 3.90% Senior Notes due September 30April 7, 2030 2032 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 75,000,000 aggregate principal amount of its 6.476.66% Senior Notes Guaranteed Notes, due September 30July 31, 2030 2015 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 30,000,000 aggregate principal amount of its 6.473.11% Senior Notes Notes, due September 30October 1, 2030 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $110,000,000 40,000,000 aggregate principal amount of its 6.474.49% Senior Notes Notes, Series E, due September 30August 16, 2030 2052 (the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. SECTION 2.